Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial

Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial

A candidate AS01-adjuvanted vaccine containing four surface proteins from non-typable Haemophilus influenzae and Moraxella catarrhalis (NTHi-Mcat) has been developed to help prevent exacerbations of chronic obstructive pulmonary disease (COPD). Sequential administration of different vaccines contain...

Full description

Bibliographic Details
Main Authors: Ilaria Galgani, Airi Põder, Rain Jõgi, Veli-Jukka Anttila, Stefano Milleri, Alberto M. Borobia, Odile Launay, Marco Testa, Daniela Casula, Luca Grassano, Annaelisa Tasciotti, Marie Dozot, Ashwani K. Arora
Format: Article
Language:English
Published: Taylor & Francis Group 2023-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
non-typable haemophilus influenzae
moraxella catarrhalis
chronic obstructive pulmonary disease
recombinant zoster vaccine
non-inferiority
immune response
adjuvant system
as01
Online Access:http://dx.doi.org/10.1080/21645515.2023.2187194

Internet

http://dx.doi.org/10.1080/21645515.2023.2187194

Similar Items